Sub-Acute Stroke Rehabilitation With AMES

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

83 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-01

Study Completion Date

2011-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The AMES device is designed to produce functional cortical changes by:(1) assisting the subject as he/she attempts to move the limb (assisted movement) and (2) enhancing movement sensation by vibrating the muscles during movement (enhanced sensation). The primary hypothesis is that the combination of assisted movement and enhanced sensation from muscle vibration can increase the amount of motor recovery in individuals disabled by a stroke.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AMES Treatment of the Impaired Leg in Chronic Stroke Patients

NCT01378637

Stroke Cerebrovascular Accident Hemiparesis

UNKNOWN PHASE1/PHASE2

Electrically Assisted Movement Therapy

NCT02563886

Cerebrovascular Accident

UNKNOWN NA

Encouragement-induced Movement Therapy in Daily Life

NCT03294187

Stroke

COMPLETED NA

Assisted Movement Neuro-rehabilitation: VA Multi-site Clinical Trial

NCT00223808

Cerebrovascular Disorders Hemiplegia

COMPLETED PHASE3

Robotic Upper-Limb Neurorehabilitation in Chronic Stroke Patient

NCT00037934

Stroke

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Approximately 700,000 U.S. citizens have a stroke each year with about half ending up with significant motor disabilities. There are an estimated 5 million stroke survivors in the U.S., making strokes the leading cause of long-term disability in the U.S.. Existing rehabilitation therapies have not been effective in returning all stroke survivors to full motor recovery.

The AMES device was designed to be able to provide therapy for the hand (fingers/wrist). In this 18 treatment sessions, double-blinded, control study, AMES therapy will be provided in addition to the usual physician-ordered rehabilitation during the sub-acute period following a stroke. Those control subject who complete the Phase 1 placebo sessions will have the opportunity to cross-over to participate in a AMES treatment group for a Phase 2.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebrovascular Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Single crossover for only the control group participants from the controlled part of the study.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test-Phase 1

The Test Group receives 18 half-hour AMES (Assisted Movement with Enhanced Sensation) treatments with the AMES device (Test) in which the hand or wrist is moved, and the subject assists the motion while vibration (60 pulses/sec) is applied to the lengthening muscle. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.

Group Type EXPERIMENTAL

AMES device (test)

Intervention Type DEVICE

Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.

Control-Phase 1

Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) programed to provide placebo therapy. Each treatment session consisting of 30 minutes of sham therapy. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.

Group Type SHAM_COMPARATOR

AMES device (sham)

Intervention Type DEVICE

Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) in which the limb is moved, but no active assistance is provided by the subject and the vibration is delivered at a very low frequency to the shortening (i.e., rather than lengthening) muscle. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.

Crossover-Phase 2

Original Control Group receives 18 half-hour crossover treatments with the AMES device (Crossover) in which the hand or wrist is moved, and the subject assists the motion while vibration (60 pulses/sec) is applied to the lengthening muscle. Sessions to be scheduled preferably 2 to 3 times per week with each session one-half hour in length.

Group Type ACTIVE_COMPARATOR

AMES device (crossover)

Intervention Type DEVICE

Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AMES device (test)

Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.

Intervention Type DEVICE

AMES device (sham)

Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) in which the limb is moved, but no active assistance is provided by the subject and the vibration is delivered at a very low frequency to the shortening (i.e., rather than lengthening) muscle. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.

Intervention Type DEVICE

AMES device (crossover)

Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hemispheric stroke (ischemic or hemorrhagic), cortical or sub-cortical, documented by either a CT or MRI scan and associated with residual weakness in the arm and/or leg.
* First time ever stroke or previous stroke with complete resolution of motor deficit, occurring ≤4 months prior to subject enrollment.
* Age 18-80 years old.
* Moderate to severe lower-extremity paresis (defined as a leg motor Fugl-Meyer score of ≥6 and ≤22 out of a possible 34.
* Moderate to severe upper-extremity paresis (defined as an arm motor Fugl-Meyer score of ≥6 and ≤43 out of a possible 66.
* Visible voluntary movement of the ankle in at least one direction: dorsiflexion or plantarflexion for the ankle and flexion or extension for the hand.
* At least partially functioning proprioception from the paretic arm or leg-capable of correctly identifying, ≥70% of the time, the direction of passive joint rotation (i.e., flexion-extension) with eyes closed.
* Physically and cognitively capable of consenting to and complying with the protocol.
* Score of \<19 out of 63 on the 21-question version of the Beck Depression Inventory.
* Subject or legally authorized representative must be capable of providing informed consent.-

Exclusion Criteria

* Complete flaccidity of the hand, wrist, and ankle.
* Pathological neurological/physical conditions, other than stroke, impairing the function of the impaired arm or leg or resulting in pain in either the arm or leg.
* Spinal cord injury, arthritis, or fractures of affected limbs that have resulted in loss of range of motion.
* Peripheral nerve injury or neuropathy resulting in significant motor or sensory loss in the limb being considered for testing.
* Cardiopulmonary compromise including but not limited to uncontrolled hypertension or angina, deep vein thrombosis, decompensated congestive heart failure, myocardial infarction, heart irregularities, or exercise intolerance.
* Major active psychiatric disorder.
* Severe apraxia; inability to understand verbal (English) directions; or inability to communicate adequately with study personnel.
* Size of arm or leg incompatible with the AMES device.
* Severe contractures or decreased range of motion that would prohibit comfortable positioning or tolerance of the device
* Skin condition not able to tolerate use of the AMES device.
* Any progressive neurodegenerative disorder affecting the motor system.
* Uncontrolled seizure disorder.
* Current abuse of alcohol or drugs.
* Terminal illness with anticipated survival of \<12 months.
* Current or planned concurrent participation in another study or clinical trial.
* NIH Stroke Scale, following scores: Item 1a \> 0; Item 1c \> 0; Item 2 \> 0; Item 3 \> 0; Item 9 \> 2; Item 10 \> 1; Item 11 \> 1 (based on exam by Study Physician).
* Intent to receive Botox injections, initiation of antispasmodic medication, or use any other robotic (e.g., MANUS, Locomat) or stimulation device (e.g., Bioness) while participating in the AMES trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No